Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

Journal of Clinical Investigation

Volumn 118, Issue 1, 2008, Pages 376-386

  McNamara II, James O ^a,f   Kolonias, Despina ^b   Pastor, Fernando ^b   Mittler, Robert S ^c   Chen, Lieping ^d   Giangrande, Paloma H ^a,f   Sullenger, Bruce ^a   Gilboa, Eli ^b,e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CD137 ANTIGEN; IMMUNOGLOBULIN G2A ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL LINE; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR REJECTION;

ANIMALS; ANTIBODIES; ANTIGENS, CD137; APTAMERS, NUCLEOTIDE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MASTOCYTOMA; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION;

EID: 38149096315     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33365     Document Type: Article

References (54)

1. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-620.
2. Sica, G., and Chen, L. 2000. Modulation of the immune response through 4-1BB. Adv. Exp. Med. Biol. 465:355-362.
3. Vinay, D.S., and Kwon, B.S. 1998. Role of 4-1BB in immune responses. Semin. Immunol. 10:481-489.
4. Watts, T.H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23-68.
5. Guinn, B.A., et al. 2001. 4-1BBL enhances antitumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell. Immunol. 210:56-65.
6. Martinet, O., et al. 2000. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J. Natl. Cancer Inst. 92:931-936.
7. Melero, I., et al. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J. Immunol. 28:1116-1121.
8. Mogi, S., et al. 2000. Tumour rejection by gene transfer of 4-1BB ligand into a CD80 (+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology. 101:541-547.
9. Ye, Z., et al. 2002. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8:343-348.
10. Melero, I., et al. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682-685.
11. May, K.F., Jr., Chen, L., Zheng, P., and Liu, Y. 2002. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62:3459-3465.
12. Taraban, V.Y., et al. 2002. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32:3617-3627.
13. Miller, R.E., et al. 2002. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169:1792-1800.
14. Wilcox, R.A., et al. 2002. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109:651-659.
15. Hirano, F., et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089-1096.
16. Kocak, E., et al. 2006. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66:7276-7284.
17. Martinet, O., et al. 2002. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther. 9:786-792.
18. Ito, F., et al. 2004. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64:8411-8419.
19. Waldmann, T.A., and Morris, J.C. 2006. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv. Immunol. 90:83-131.
20. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., and Chen, L. 2007. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer. 7:95-106.
21. Tuerk, C., and Gold, L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 249:505-510.
22. Ellington, A.D., and Szostak, J.W. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature. 346:818-822.
23. Gold, L. 1995. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270:13581-13584.
24. White, R.R., Sullenger, B.A., and Rusconi, C.P. 2000. Developing aptamers into therapeutics. J. Clin. Invest. 106:929-934.
25. Nimjee, S.M., Rusconi, C.P., and Sullenger, B.A. 2005. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56:555-583.
26. Ng, E.W., et al. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5:123-132.
27. Dyke, C.K., et al. 2006. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 114:2490-2497.
28. Santulli-Marotto, S., Nair, S.K., Rusconi, C., Sullenger, B., and Gilboa, E. 2003. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63:7483-7489.
29. Harris, L.J., et al. 1992. The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature. 360:369-372.
30. Alberts, B., et al. 2002. Molecular biology of the cell. 4th edition. Garland Science. New York, New York, USA/London, United Kingdom. 1616 pp.
31. Deane, J.A., and Bolland, S. 2006. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J. Immunol. 177:6573-6578.
32. Akira, S., Uematsu, S., and Takeuchi, O. 2006. Pathogen recognition and innate immunity. Cell. 124:783-801.
33. Williams, B.R. 1999. PKR; a sentinel kinase for cellular stress. Oncogene. 18:6112-6120.
34. Agrawal, S., and Kandimalla, E.R. 2004. Role of Toll-like receptors in antisense and siRNA [erratum 2005, 23:117]. Nat. Biotechnol. 22:1533-1537.
35. Marques, J.T., and Williams, B.R. 2005. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23:1399-1405.
36. Haswell, L.E., Glennie, M.J., and Al-Shamkhani, A. 2001. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur. J. Immunol. 31:3094-3100.
37. Holler, N., et al. 2003. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23:1428-1440.
38. Beigelman, L., et al. 1995. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem. 270:25702-25708.
39. Pieken, W.A., Olsen, D.B., Benseler, F., Aurup, H., and Eckstein, F. 1991. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science. 253:314-317.
40. Tucker, C.E., et al. 1999. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J. Chromatogr. B Biomed. Sci. Appl. 732:203-212.
41. Willis, M.C., et al. 1998. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 9:573-582.
42. Uno, T., et al. 2006. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12:693-698.
43. Niu, L., et al. 2007. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J. Immunol. 178:4194-4213.
44. Sun, Y., et al. 2002. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168:1457-1465.
45. Sun, Y., et al. 2002. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. 8:1405-1413.
46. Foell, J., et al. 2003. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J. Clin. Invest. 111:1505-1518.
47. Seo, S.K., et al. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10:1088-1094.
48. Myers, L.M., and Vella, A.T. 2005. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol. 26:440-446.
49. Fitzwater, T., and Polisky, B. 1996. A SELEX primer. Methods Enzymol. 267:275-301.
50. Sousa, R., and Padilla, R. 1995. A mutant T7 RNA polymerase as a DNA polymerase. EMBO J. 14:4609-4621.
51. Wong, I., and Lohman, T.M. 1993. A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc. Natl. Acad. Sci. U. S. A. 90:5428-5432.
52. Layzer, J.M., and Sullenger, B.A. 2007. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides. 17:1-11.
53. Mathews, D.H., et al. 2004. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc. Natl. Acad. Sci. U. S. A. 101:7287-7292.
54. Shuford, W.W., et al. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47-55.